(1)
Renowned immunologist and T cell engineering expert awarded distinguished prize for conducting fundamental translational research of substantial significance for medicine
Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that the company's co-founder, Board member and Chairman of its Scientific Advisory Board, Ton Schumacher, Ph.D., has been awarded the 2021 Jeantet-Collen Prize for Translational Medicine. Awarded each year by the Louis-Jeantet Foundation to leading-edge researchers who are active in the member states of the Council of Europe, the prize is intended to foster scientific excellence and encourage the continuation of innovative research projects.